Compare Paychex, Inc. (PAYX) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Stryker Corporation — how do they compare? Paychex, Inc. trades at $114.91 (market cap $40.85B), while Stryker Corporation trades at $277.3 (market cap $105.63B). The key difference: Stryker Corporation is far larger — about 2.6× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.15%). Which is the better fit depends on your goals.
| PAYX | SYK | |
|---|---|---|
Market Cap | $40.85B | $105.63B |
Sector | Industrials | Technology |
52-Week High | $135.46 | $388.79 |
52-Week Low | $85.57 | $275.39 |
Enterprise Value | $44.33B | $117.10B |
Dividend Yield | 4.15% | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $116.93, down 3.93% in the last session. The stock shows strong profitability with a net income margin of 27.03% and ROE of 44.77%. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.32 surpassing the $1.31 estimate. Technical indicators are mixed, with a bearish moving average signal but RSI suggesting potential oversold conditions. The company continues to expand its AI-driven WISE platform, enhancing service efficiency for small businesses.
The outlook for PAYX is cautiously optimistic, supported by robust cash flow and strategic AI integration. However, risks include elevated valuation multiples and competitive pressures in the HR solutions space. Analyst consensus is a 'Hold' with a $120 price target, indicating limited near-term upside from current levels amid balanced growth and risk factors.
Stryker Corporation (SYK) trades at $276.43, down 8.81% over 24 hours, reflecting bearish technical signals but strong fundamentals. The stock shows robust profitability with a 14.43% net income margin and consistent earnings beats in recent quarters. Recent developments include the launch of an FDA-cleared surgical app for Apple Vision Pro and the acquisition of ZuriMED to expand shoulder care offerings. Analyst consensus remains strongly bullish with a $372.89 price target, though ongoing securities fraud investigations pose near-term sentiment risks.
Outlook is positive long-term due to solid financial health, innovation pipeline, and institutional support, but investors face volatility from legal probes and technical bearishness. The stock's current dip may present a buying opportunity for those confident in Stryker's market position and growth trajectory, balanced against regulatory and market risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
